Nemera expands its insulin pen’s offer in Brazil
![](/46/pdcnewsitem/08/48/99/post.png)
This partnership expands offer of diabetes medicines in the country;
Nemera’s Advapen launch happens under the trade name Lifepen® for the administration of Glargilin insulin for the treatment of diabetes
A pioneer in biotechnological medicines in Brazil, BIOMM is launching Nemera’s Advapen under the trade name Lifepen®
for the administration of Glargilin insulin for the treatment of
diabetes.
Nemera and Biomm sign partnership agreement to commercialize reusable insulin pen in Brazil
![Nemera](https://www.cphi-online.com/c245079th_S-comp245079.jpg)
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance